IMM 27M
Alternative Names: IMM-27M; SYN-27MLatest Information Update: 21 Aug 2024
At a glance
- Originator ImmuneOnco Biopharma
- Class Antineoplastics; Gene therapies; Immunoglobulins; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Aug 2024 ImmuneOnco Biopharmaceuticals plans a clinical trial for Solid tumours (combination therapy, late stage disease) in China in July 2024
- 01 Aug 2024 ImmuneOnco Biopharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (injection) (NCT05235438)
- 01 Aug 2024 IMM 27M licensed to Instil Bio worldwide excluding Greater China including Taiwan, Macau, and Hong Kong